Millipore Scientist To Lead PDA Web Seminar On Innovative Testing Methods For Detecting Mycoplasma Contamination
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, will lead a web-based seminar on detection of Mycoplasma and viral contamination, a subject of heightened interest in biopharmaceutical manufacturing. The event will be held on Thursday, October 29, 2009 from 1-2:30pm EST and is sponsored by the Parenteral Drug Association (PDA), a nonprofit international organization and a leading global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical community.
The webinar will present an integrated, membrane-based approach that increases sensitivity and assay robustness when testing for Mycoplasma or virus that may be present in very small quantities compared to mammalian cells; this approach also decreases time-to-result and allows real-time monitoring of high-value processes and products for the biopharmaceutical industry.
Millipore Corporation senior scientist Julie R. Murrell, PhD, will be the webinar presenter. Dr. Murrell is a leader in bioprocess and bioscience product development and has led a Millipore early technology assessment group for the past 3 years. Initially involved in integrating microbe detection and identification with Millipore sample preparation devices, Dr. Murrell is also identifying new detection technologies for contaminant monitoring in biopharmaceutical manufacturing.
According to Dr. Murrell, "Mycoplasma and viral detection are traditionally based on growth and infectivity assays, which are time-consuming and labor intensive. Traditional microbiological methods could advantageously be replaced by nucleic acid amplification testing for earlier in-process detection."
"With increasing pressure on biopharmaceutical companies to understand and control their manufacturing processes and assure their products are contaminant free, the industry is looking at rapid systems as a viable alternative to traditional culture-based testing for Mycoplasma and virus testing in biomanufacturing processes," stated Roland Heinrich, Ph.D., Vice President, Process Monitoring Tools. "As the industry evolves, so must the technologies and Millipore is committed to advancing rapid microbial detection methods as demonstrated in the webinar presented by Dr. Murrell."
For an agenda and information on registering for the webinar, entitled "Membrane-based Sample Preparation for Mycoplasma or Virus Capture, Lysis, and Nucleic Acid Purification and Detection," please visit: http://www.pda.org/MainMenuCategory/GlobalEventCalendarandRegistration/WebSeminars/Membrane-based-Sample-Preparation-for-Mycoplasma-or-Virus-Capture-Lysis-and-Nucleic-Acid-Purificat.aspx
About The Parenteral Drug Association (PDA)
The Parenteral Drug Association (PDA) is a nonprofit international organization and a leading global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical community. PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its more than 11,000 members worldwide. For more information, visit www.pda.org.
About Millipore
Millipore is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 5,900 employees worldwide. For more information, visit http://www.millipore.com.
SOURCE: Millipore Corporation